Novel Treatment in Age-related Macular Degeneration

Posted On 2022-01-06 12:07:13

The Series on “Novel Treatment in Age-related Macular Degeneration” is edited by Sayena Jabbehdari, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.

Sayena Jabbehdari is a clinician-scientist in the field of Ophthalmology at the Illinois Eye and Ear Infirmary at University of Illinois at Chicago (UIC). She is the member of American Academy of Ophthalmology (AAO) and the Association for Research in Vision and Ophthalmology (ARVO). She has more than 53 publications in peer reviewed journals and three book chapters in the Cornea book (5th edition), and the Pediatric Retina book. Her research interest is diet modification and antioxidant therapy to reverse aging pathways in the retinal diseases.

The main purpose of this series:
Age-related macular degeneration (AMD or ARMD) is the first blindness cause in Western countries and also the third irreversible disease in the world. AMD is often featured by progressive visual impairment, which seriously affects life qualities of the elderly. Discussion and comparison of novel therapies for age-related macular degeneration could benefit the patients and inspire us the in-depth exploration in the ophthalmology field.

Review Article on Novel Treatment in Age-related Macular Degeneration
Novel mitochondrial therapies for the treatment of age-related macular degeneration
Aneesha Kalur, Justin Muste, Carolina C. S. Valentim, Amogh Iyer, Rishi P. Singh

Narrative review-drug delivery in age-related macular degeneration
Rachel Israilevich, Raziyeh Mahmoudzadeh, Mirataollah Salabati, David Xu

Statins for age related macular degeneration: promising but unproven
Martin A. Mainster, Ahmed Al-Janabi, Ana Boris Moreno Andrade, Gerardo Ledesma-Gil

A narrative review on the role of abicipar in age-related macular degeneration
Hossein Ghahvechian, Ahmed B. Sallam, Sayena Jabbehdari

Narrative review of risuteganib for the treatment of dry age-related macular degeneration (AMD)
Mark A. Solinski, Veena R. Raiji

Molecular structure, pharmacokinetics and clinical evidence of brolucizumab: a narrative review
Francesco Pignatelli, Alfredo Niro, Fedele Passidomo, Giuseppe Addabbo

Novel treatments and genetics of age-related macular degeneration-a narrative review
Amir Arabi, Toktam Shahraki

Amniotic membrane as a novel treatment in age-related macular degeneration: a narrative review
Abbas Habibi, Maryam Ashraf Khorasani

The series “Novel Treatment in Age-related Macular Degeneration” was commissioned by the editorial office, Annals of Eye Science without any sponsorship or funding. Sayena Jabbehdari served as the unpaid Guest Editor for the series.